Elixicure reported on Monday that its Elixicure CBD-infused pain relief products has received US Food and Drug Administration (FDA) over-the-counter drug registration certification following a successful year-long process.
The announcement was made by the company's chief of business development, Yaniv Kotler.
To date, this registration and certification marks the very first and currently the only, Over-The-Counter (OTC) Topical drug with Cannabidiol (CBD), revealed the company.
According to the company, Elixicure is an all-natural, non-addictive pain relief cream developed to help reduce inflammation, swelling, aches and pains. The product contains Cannabidiol (CBD) extract, one of the main active chemical compounds naturally found in the hemp plant and contributing to the beneficial medicinal qualities of hemp. Unlike THC, hemp CBD extract does not make you feel "high".
In conjunction, the company's Elixicure is manufactured by Honest Globe, developers of luxury cosmetic, health and beauty products. The products are made with naturally-derived ingredients, using certified industry-standard manufacturing processes.
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
HistoIndex partners Houston Research Institute
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Alvotech launches first-in-market golimumab biosimilar in Europe
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011